Montgomery et al., 2009 - Google Patents
Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41Montgomery et al., 2009
View PDF- Document ID
- 3975496120186332591
- Author
- Montgomery D
- Wang Y
- Hrin R
- Luftig M
- Su B
- Miller M
- Wang F
- Haytko P
- Huang L
- Vitelli S
- Condra J
- Liu X
- Hampton R
- Carfi A
- Pessi A
- Bianchi E
- Joyce J
- Lloyd C
- Geleziunas R
- Bramhill D
- King V
- Finnefrock A
- Strohl W
- An Z
- Publication year
- Publication venue
- MAbs
External Links
Snippet
The human D5 monoclonal antibody binds to the highly conserved hydrophobic pocket on the N-terminal heptad repeat (NHR) trimer of HIV-1 gp41 and exhibits modest yet relatively broad neutralization activity. Both binding and neutralization depend on residues in the …
- 241000713772 Human immunodeficiency virus 1 0 title abstract description 45
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
- C07K16/1036—Retroviridae, e.g. leukemia viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017225144B2 (en) | N-Terminal Deleted GP120 Immunogens | |
| Montgomery et al. | Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41 | |
| CN104080805B (en) | Neutralizing gp41 antibodies and their use | |
| Brunel et al. | Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody | |
| WO2021244089A1 (en) | Sars-cov-2 spike protein binding molecule and application thereof | |
| Silva et al. | Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronaviruses | |
| WO2011046623A2 (en) | Hiv-1 antibodies | |
| Ong et al. | Preparation of biologically active single-chain variable antibody fragments that target the HIV-1 GP120 v3 loop | |
| US20250051454A1 (en) | Antibodies that target hla-e-host peptide complexes and uses thereof | |
| WO2021108448A1 (en) | Anti-yellow fever virus antibodies, and methods of their generation and use | |
| Opalka et al. | Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay | |
| Kim et al. | A novel bispecific antibody dual-targeting approach for enhanced neutralization against fast-evolving SARS-CoV-2 variants | |
| Dorgham et al. | Immunogenicity of HIV type 1 gp120 CD4 binding site phage mimotopes | |
| EP1765398B1 (en) | Human antibodies interacting with hiv gp41 | |
| WO2022208453A1 (en) | Peptides and antibody fusions that bind to sars-cov-2 and methods of using same | |
| WO2018053328A1 (en) | Bispecific molecules comprising an hiv-1 envelope targeting arm | |
| WO2006089678A2 (en) | Antibodies and peptides binding to hiv tat, and uses thereof | |
| CN114867744B (en) | Anti-yellow fever virus antibodies and methods of making and using the same | |
| WO2024206190A1 (en) | Antibodies that target hla-e-host peptide complexes and uses thereof | |
| EP4388012A1 (en) | Antibodies that target hla-e-host peptide complexes and uses thereof | |
| HK40077777A (en) | Anti-yellow fever virus antibodies, and methods of their generation and use | |
| CA2509387A1 (en) | Peptide oligomers for use as hiv vaccines | |
| Wilson et al. | An Affinity-Enhanced Neutralizing Antibody | |
| US20140148586A1 (en) | Designing a soluble full-length hiv-1 gp41 trimer | |
| Martinez et al. | Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses |